Literature DB >> 3193137

Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models.

T Riise1, M Grønning, J A Aarli, H Nyland, J P Larsen, A Edland.   

Abstract

To determine if such factors as first symptom, sex, age at onset and initial clinical course have any influence on life expectancy of multiple sclerosis patients, a survival analysis from date of diagnosis for 598 MS-patients in Norway was performed. To study the effect of all the variables simultaneously we used the Cox proportional hazards regression model with incomplete data. Median survival time was 27 years after diagnosis. The variable which most strongly predicted the duration of the disease was age at onset. High age at onset and a progressive course of the disease were correlated with a more unfavourable prognosis. The onset symptom, vertigo, was also correlated with a shorter life expectancy. No significant effect of sex was found. We found in this material an indication of improved survival over the study period.

Entities:  

Mesh:

Year:  1988        PMID: 3193137     DOI: 10.1016/0895-4356(88)90041-8

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  12 in total

1.  Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.

Authors:  K Lauer; W Firnhaber
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

Review 2.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

3.  Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway.

Authors:  R Midgard; T Riise; H Nyland
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 4.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

5.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

6.  Pre-existing central nervous system lesions negate cytokine requirements for regional experimental autoimmune encephalomyelitis development.

Authors:  Xin Li; Jason R Lees
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

7.  Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway.

Authors:  R Midgard; G Albrektsen; T Riise; G Kvåle; H Nyland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

8.  Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Authors:  Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.

Authors:  Douglas S Goodin; George C Ebers; Gary Cutter; Stuart D Cook; Timothy O'Donnell; Anthony T Reder; Marcelo Kremenchutzky; Joel Oger; Mark Rametta; Karola Beckmann; Volker Knappertz
Journal:  BMJ Open       Date:  2012-11-30       Impact factor: 2.692

10.  Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study.

Authors:  Bilge Piri Çinar; Serkan Özakbaş
Journal:  Noro Psikiyatr Ars       Date:  2018-03-19       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.